CD33

Now a pipeline stop at Bristol Myers Squibb.

Aurum Therapeutics says BMS discontinued the CD33-directed degrader antibody conjugate that came from Aurum after reviewing phase one data.

The program was being developed for acute myeloid leukemia and myelodysplastic syndromes.

Fierce reports that BMS paid a hundred million upfront in twenty twenty-three, and ending development removes Aurum's chance to earn up to eighty million dollars in clinical development milestones.

So I think that's great.

You know, our group in particular, we had done a CD33 CAR T cell trial in AML.

And of course, there you are targeting hematopoietic precursors and precursors.

had the option of using transplant, you know, of having transplant available as a safety mechanism in case of myelodiplasia.

Newer molecules are also being developed, including those treating liquid tumors like leukemia.

AML can now be treated by CD33 labeled actinium-225.

And actinium-labeled CEA and actinium-labeled FAPI are newer agents that are able to use to treat gastrointestinal tumors.

In fact, there's over 30 trials using targeted actinium treatments, and there are over 100, if you count other agents, as well as combinations with conventional chemotherapies and immunotherapies.